Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., May 12, 2026...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form S-1 - General form for registration of securities under the Securities Act of 1933

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 PR Newswire STATEN...

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PR Newswire STATEN ISLAND, N.Y., April...

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update PR Newswire...

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR...

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire STATEN...

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y., March 30...

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., March...

Form 8-K - Current report

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment...

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business...

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y., Feb. 2, 2026 STATEN...

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx...